EU's medical technology industry group presses for exclusion of medical equipment and diagnostic tools from trade conflict
In the ongoing trade dispute between the United States and the European Union, two influential industry bodies, MedTech Europe and AdvaMed, have been actively advocating for the exclusion of medical devices and diagnostics from any trade tariffs and export restrictions.
The European Commission's draft proposal for countermeasures to U.S. tariffs targets a broad range of devices, diagnostics, and components. Recognising the potential disruption to supply chains and the healthcare system, MedTech Europe has publicly called on the EU to exempt medical technologies and essential inputs, such as raw materials and spare parts, from retaliatory tariffs.
AdvaMed, the U.S. counterpart of MedTech Europe, has made similar pleas for tariff relief. They advocate for a “zero-for-zero” reciprocal tariff approach on medtech products, pushing for regulatory convergence and strong trade ties with key partners like the EU and Switzerland.
The draft list of products includes over 800 trade codes related to medical technologies, covering finished goods as well as various core components necessary for the functioning of medical devices and diagnostics. Replacing components is not a simple option in some cases, and no alternative may exist. Where substitutes are possible, the process of revalidation is lengthy and resource-intensive to ensure the same high standards and safety are met.
Delays to access to medical technologies ultimately affect patients. MedTech Europe warns that companies may struggle to adapt their supply chains before patient care is affected. Negotiators have until July 9 to reach an agreement or extend talks, after which the U.S. may reimpose tariffs at a higher rate. Potential reimposition of higher tariffs by the U.S. could trigger retaliatory measures from the EU, which MedTech Europe wants to avoid.
Both organisations' efforts reflect an ongoing, strategic effort to shield the medtech industry from trade conflicts and tariffs that could impair the availability and competitiveness of medical devices and diagnostics on both sides of the Atlantic. The Recommended Reading article "AdvaMed CEO Scott Whitaker pleads for tariff relief in Senate hearing" discusses the issue further, while "Trump's tariffs: Tracking the status of international trade actions" provides updates on the status of international trade actions.
In summary, while no specific final trade agreement text is cited, both MedTech Europe and AdvaMed have been effective and persistent in lobbying for the exemption of medical devices and diagnostics from trade tariffs and export restrictions in U.S.-EU trade relations to date.
- The AI-driven news analytics revealed a spike in articles about the ongoing trade dispute between the United States and the European Union, particularly those concerning medical devices and diagnostics.
- In light of the potential impact on patient health-and-wellness, the medtech industry, through its powerful bodies like MedTech Europe and AdvaMed, has been actively advocating for the safety of medical innovations and technology.
- The medtech business sector has been vocal about the importance of maintaining strong trade ties, as advocated by AdvaMed, to ensure the availability and competitiveness of medical devices and diagnostics in the health-and-wellness arena.
- The European Commission's draft proposal for countermeasures to U.S. tariffs threatens to disrupt the supply chain of essential medical devices and diagnostics, potentially delaying access to these critical components for patients.
- Recognizing the resource-intensive process of revalidation for alternative components, MedTech Europe and AdvaMed have been urging regulators to exempt medical technologies and essential inputs from retaliatory tariffs to protect the healthcare industry.
- The financial implications of the ongoing trade dispute extend beyond the medtech industry, with potential impacts on both the general-news landscape and the broader political economy, as negotiations progress.
- In a recent Senate hearing, AdvaMed CEO Scott Whitaker pleaded for tariff relief, emphasizing the importance of medtech products and the need for regulatory convergence, as well as strong trade ties with key partners like the EU and Switzerland.
- As the deadline for a potential trade agreement approaches, the medtech industry continues to support the exclusion of medical devices and diagnostics from trade tariffs and export restrictions, aiming to ensure uninterrupted access to these crucial health-and-wellness solutions.
